Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), creatinine, troponin, NT-proBNP and pre- and post-treatment echocardiograms, including ejection fraction (EF), average global longitudinal strain and compliance. Pre-treatment elevations in NT-proBNP and BP, as well as abnormal cardiac strain were common. A rise in NT-proBNP occurred frequently post-treatment often without corresponding cardiopulmonary symptoms. A rise in creatinine was common, lessened with hydration and often reversible. All patients had a normal EF pre-treatment. Five patients experienced a significant cardiac event (four decline in EF and one myocardial infarction), of which 2 (3.2%) were considered probably attributable to Cfz. None were rechallenged with Cfz. The ideal strategy for identifying patients at risk for cardiac events, and parameters by which to monitor for early toxicity have not been established; however, it appears baseline echocardiographic testing is not consistently predictive of toxicity. The toxicities observed suggest an endothelial mechanism and further clinical trials are needed to determine whether or not this represents a class effect or is Cfz specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citation
Cited by
The proteasome and proteasome inhibitors in multiple myeloma
Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9707-8 · Cited by 340
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
Waxman, A. J., Clasen, S., Hwang, W.-T., Garfall, A., Vogl, D. T., Carver, J., O’Quinn, R., Cohen, A. D., Stadtmauer, E. A., Ky, B., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4519 · Cited by 286
Cornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00231 · Cited by 198
The safety of bortezomib for the treatment of multiple myeloma
Cengiz Seval, G., & Beksac, M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1513487 · Cited by 117
Metadata
- Authors
- Rosenthal, A., Luthi, J., Belohlavek, M., Kortüm, K. M., Mookadam, F., Mayo, A., Fonseca, R., Bergsagel, P. L., Reeder, C. B., Mikhael, J. R., & Stewart, A. K.
- Venue
- Blood Cancer Journal
- Published
- 2016-01-15
- Volume
- 6
- Issue
- 1
- Pages
- e384-e384
- ISSN
- 2044-5385 (ISSN-L)
- OpenAlex
- W2234403337
- Cited by
- 75
- References
- 1
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? https://app.cochat.ai/papers/10.1038/bcj.2015.112
- The paper
- Rosenthal, A., Luthi, J., Belohlavek, M., Kortüm, K. M., Mookadam, F., Mayo, A., Fonseca, R., Bergsagel, P. L., Reeder, C. B., Mikhael, J. R., & Stewart, A. K. (2016). Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer Journal. https://doi.org/10.1038/bcj.2015.112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.